Roth Capital Sets Dianthus Therapeutics Price Target at $113
Benzinga reports that Roth Capital initiated coverage of Dianthus Therapeutics with a Buy rating and a $113 price target.
Related stories
Intel Signals Slower Growth, Forecasts Q4 Revenue of $15-$16 Billion
Intel forecast Q4 revenue of $15-$16 billion as the PC market remains under pressure.
M impact | EQUITY | Oct 29, 2026, 08:15 PM UTC
Alignment Healthcare Reports Third-Quarter Results and Updates Full-Year Outlook
Alignment Healthcare reported results for the quarter ended Sept. 30, 2026, and updated its full-year outlook.
M impact | EQUITY | Oct 29, 2026, 08:04 PM UTC
Intel CFO Expects Similar Q1 Revenue Impact From Kiryat Gat Explosion
Intel CFO David Zinsner said in a Reuters interview that the explosion at the Kiryat Gat fab is expected to have a similar revenue impact in Q1.
M impact | EQUITY | Oct 29, 2026, 08:04 PM UTC
Intel Still Assessing Whether Fab Explosion Impact Exceeds Estimates
Intel CFO David Zinsner said the company is still assessing whether the fab explosion’s impact will extend beyond current estimates.
L impact | EQUITY | Oct 29, 2026, 08:03 PM UTC
Symbotic Sets Date to Report Fourth-Quarter and Fiscal 2026 Results
Symbotic announced the date for reporting its fourth-quarter and fiscal 2026 financial results.
M impact | EQUITY | Oct 29, 2026, 08:03 PM UTC
Intel Still Assessing Which Kiryat Gat Wafers Can Be Salvaged
Intel CFO David Zinsner said the company is assessing which wafers at its Kiryat Gat fab are salvageable for use and sale.
L impact | EQUITY | Oct 29, 2026, 08:03 PM UTC